Lipocine Inc (LPCN)

$4.61

+0.53

(+12.99%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $4.08
    $4.84
    $4.61
    downward going graph

    11.5%

    Downside

    Day's Volatility :15.66%

    Upside

    4.7%

    downward going graph
  • $2.31
    $11.79
    $4.61
    downward going graph

    49.89%

    Downside

    52 Weeks Volatility :80.41%

    Upside

    60.9%

    downward going graph

Returns

PeriodLipocine IncIndex (Russel 2000)
3 Months
-51.42%
0.0%
6 Months
-1.71%
0.0%
1 Year
21.64%
0.0%
3 Years
-75.57%
-20.0%

Highlights

Market Capitalization
21.3M
Book Value
$3.97
Earnings Per Share (EPS)
-1.62
PEG Ratio
0.0
Wall Street Target Price
33.0
Profit Margin
-176.8%
Operating Margin TTM
-3676.18%
Return On Assets TTM
-22.67%
Return On Equity TTM
-34.12%
Revenue TTM
4.8M
Revenue Per Share TTM
0.9
Quarterly Revenue Growth YOY
13751.900000000001%
Gross Profit TTM
500.0K
EBITDA
-9.7M
Diluted Eps TTM
-1.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.92
EPS Estimate Next Year
-0.93
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Lipocine Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 615.84%

Current $4.61
Target $33.00

Technicals Summary

Sell

Neutral

Buy

Lipocine Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lipocine Inc
Lipocine Inc
21.96%
-1.71%
21.64%
-75.57%
-90.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.3%
20.26%
38.56%
78.77%
303.42%
Novo Nordisk A/s
Novo Nordisk A/s
1.92%
1.8%
42.06%
173.92%
453.76%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
0.91%
78.6%
37.4%
41.12%
212.93%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.95%
18.74%
38.91%
157.61%
173.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lipocine Inc
Lipocine Inc
NA
NA
0.0
-0.92
-0.34
-0.23
NA
3.97
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.86
30.86
1.59
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
46.01
46.01
2.08
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lipocine Inc
Lipocine Inc
Buy
$21.3M
-90.71%
NA
-176.8%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$128.4B
303.42%
30.86
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$600.4B
453.76%
46.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.1B
212.93%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.3B
173.37%
32.84
-4.74%

Insights on Lipocine Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 20.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 173.9% return, outperforming this stock by 249.5%

Institutional Holdings

  • Vanguard Group Inc

    4.14%

  • BlackRock Inc

    1.67%

  • Geode Capital Management, LLC

    0.99%

  • Renaissance Technologies Corp

    0.48%

  • Susquehanna International Group, LLP

    0.47%

  • State Street Corp

    0.35%

Company Information

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.

Organization
Lipocine Inc
Employees
17
CEO
Dr. Mahesh V. Patel Ph.D.
Industry
Health Technology

Discover More

FAQs